Clinical trial · no report yet · Phase 2
FORT
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
- NCT04984343 ↗
- Terminated
- Weill Medical College of Cornell University
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 15 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Prostate Cancer
- Interventions
- Radiation Therapy
- Arms
- 5 radiation treatments - ARM 1 · Experimental
- 2 radiation treatments - ARM 2 · Active comparator
- Enrollment
- 33
- Primary outcomes
- Change in the number of patient-reported GI symptoms using the Expanded Prostate Cancer Index Composite (EPIC)
- Sponsor
- Weill Medical College of Cornell University with Viewray Inc., Progenics Pharmaceuticals, Inc.
- Start
- Feb 11, 2022
- Primary completion
- Dec 31, 2025
- Results posted
- No
- Registry record
- NCT04984343 · updated Apr 23, 2026
Publications
linked from the registry- Wolfe S, Diven MA, Marciscano AE, Zhou XK, Kishan AU, Steinberg ML, Miccio JA, Camilleri P, Nagar H. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT). BMC Cancer. 2023 Sep 30;23(1):923. doi: 10.1186/s12885-023-11430-z. PubMed 37777738